NEW YORK, February 3, 2017 /PRNewswire/ --
Stock-Callers.com is currently assessing the performances of four major
At the close of trading on Thursday, shares in Knoxville, Tennessee-based Provectus Biopharmaceuticals Inc. ended flat at $0.02 with a total trading volume of 531,389 shares. The stock is trading below its 50-day moving average by 8.46%. Shares of the Company, which engages in developing ethical pharmaceuticals for oncology and dermatology indications, have a Relative Strength Index (RSI) of 49.53.
On January 31st, 2017, Provectus Biopharma announced that it has commenced a rights offering, pursuant to which the Company is issuing subscription rights to purchase units to (i) the Company's existing common stockholders and to (ii) holders of the Company's class of warrants with an exercise price of $0.85 per share expiring June 19th, 2020. Holders will receive one subscription right for each 20 shares of common stock and each 20 Listed Warrants held as of January 26, 2017. Each Right will entitle Holders to purchase one Unit at a subscription price of $1.00 per Unit. Each Unit consists of four shares of common stock and one-half a share of Series C Convertible Preferred Stock. Access our complete research report on PVCT for free at:
Shares in Boca Raton, Florida headquartered TherapeuticsMD Inc. ended the day 1.03% higher at $5.88 with a total trading volume of 2.33 million shares. In the previous three months and since the start of this year, the stock has gained 6.52% and 1.91%, respectively. The Company's shares are trading below their 50-day moving average by 2.67%. Furthermore, shares of TherapeuticsMD, which operates as a women's health care product company, have an RSI of 51.47.
On January 11th, 2017, TherapeuticsMD announced the publication of two manuscripts detailing results of its phase-3 Rejoice Trial in Menopause. The Rejoice Trial is the pivotal phase-3 study of TX-004HR, an investigational bio-identical 17?-estradiol vaginal softgel capsule, for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar vaginal atrophy in postmenopausal women. The complimentary research report on TXMD can be downloaded at:
On Thursday, shares in Basel, Switzerland headquartered Novartis AG finished 0.46% lower at $73.08. A total volume of 4.21 million shares was traded, which was above their three months average volume of 3.57 million shares. The stock has advanced 0.34% in the last one month, 2.42% over the previous three months, and 0.33% on an YTD basis. The Company's shares are trading above their 50-day moving average by 2.75%. Additionally, shares of Novartis, which researches, develops, manufactures, and markets a range of healthcare products worldwide, have an RSI of 58.22.
On January 11th, 2017, research firm Credit Suisse downgraded the Company's stock rating from 'Outperform' to 'Neutral'.
On January 31st, 2017, Novartis announced that the European Commission has approved Votubia® dispersible tablets as an adjunctive treatment for patients aged two years and older whose refractory partial-onset seizures, with or without secondary generalization, are associated with tuberous sclerosis complex (TSC). Votubia is now the first approved pharmacologic therapy in all 28 member states of the European Union, plus Iceland and Norway, specifically for the treatment of refractory partial-onset seizures associated with TSC. Register for free on Stock-Callers.com and get access to the latest PDF format report on NVS at
New York-based Tonix Pharmaceuticals Holding Corp.'s shares recorded a trading volume of 969,397 shares at the end of yesterday's session. The stock closed the day 5.16% higher at $0.53. The Company's shares have advanced 3.92% in the last one month, 23.83% in the previous three months, and 12.74% on an YTD basis. The stock is trading above its 50-day moving average by 9.55%. Additionally, shares of Tonix Pharmaceuticals Holding, which develops medicines for common disorders of the central nervous system, have an RSI of 51.46.
On January 10th, 2017, Tonix Pharma announced details of its product pipeline and stated that it is developing TNX-601 as a first line PTSD monotherapy. TNX-601 is a novel oral formulation of tianeptine designed for daytime dosing. TNX-601 is at the pre-IND (Investigational New Drug) stage of development. The Company is also developing TNX-801 (live virus vaccine) as a potential smallpox-preventing vaccine for the national stockpile and potentially for widespread immunization. Download your free research report on TNXP at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All